These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 26529133)

  • 1. Two long-acting injectable antipsychotics for schizophrenia.
    Med Lett Drugs Ther; 2015 Nov; 57(1481):152-3. PubMed ID: 26529133
    [No Abstract]   [Full Text] [Related]  

  • 2. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.
    Naber D; Hansen K; Forray C; Baker RA; Sapin C; Beillat M; Peters-Strickland T; Nylander AG; Hertel P; Andersen HS; Eramo A; Loze JY; Potkin SG
    Schizophr Res; 2015 Oct; 168(1-2):498-504. PubMed ID: 26232241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study.
    Savitz AJ; Lane R; Nuamah I; Gopal S; Hough D
    J Am Acad Child Adolesc Psychiatry; 2015 Feb; 54(2):126-137.e1. PubMed ID: 25617253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison.
    Pae CU; Wang SM; Han C; Bahk WM; Lee SJ; Patkar AA; Masand PS; Serretti A; Emsley R
    Int Clin Psychopharmacol; 2017 Sep; 32(5):235-248. PubMed ID: 28430670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methodological challenges in indirect treatment comparisons: spotlight on a recent comparison of long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia.
    Singh A; Gopal S; Kim E; Mathews M; Kern-Sliwa J; Turkoz I; Wooller A; Berlin J
    Int Clin Psychopharmacol; 2018 Jul; 33(4):213-216. PubMed ID: 29494348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study.
    Miller BJ; Claxton A; Du Y; Weiden PJ; Potkin SG
    Schizophr Res; 2019 Jun; 208():44-48. PubMed ID: 30745067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison.
    Cameron C; Zummo J; Desai DN; Drake C; Hutton B; Kotb A; Weiden PJ
    Value Health; 2017; 20(7):876-885. PubMed ID: 28712616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Continuation of 3 Second-Generation Antipsychotic Long-Acting Injections, and Oral Paliperidone in Patients With Schizophrenia for 2 Years.
    Suzuki H; Hibino H; Inoue Y; Takaya A
    J Clin Psychopharmacol; 2018 Dec; 38(6):649-650. PubMed ID: 30334868
    [No Abstract]   [Full Text] [Related]  

  • 9. A qualitative study of patient experience when switching from paliperidone palmitate once monthly (PP1M) to paliperidone palmitate three monthly (PP3M) long-acting injectable antipsychotic.
    Lai JK; Margolese HC
    Schizophr Res; 2019 Feb; 204():443-444. PubMed ID: 30241989
    [No Abstract]   [Full Text] [Related]  

  • 10. Budget impact analysis of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
    Augusto M; Greene M; Touya M; Sweeney SM; Waters H
    J Comp Eff Res; 2018 Jul; 7(7):627-636. PubMed ID: 29694243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
    Augusto M; Greene M; Touya M; Sweeney SM; Waters H
    J Comp Eff Res; 2018 Jul; 7(7):637-650. PubMed ID: 29694244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.
    Morris MT; Tarpada SP
    Psychopharmacol Bull; 2017 May; 47(2):42-52. PubMed ID: 28626271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-month paliperidone palmitate - a new treatment option for schizophrenia.
    Bernardo M; Bioque M
    Expert Rev Clin Pharmacol; 2016 Jul; 9(7):899-904. PubMed ID: 27206330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study.
    Weiden PJ; Claxton A; Kunovac J; Walling DP; Du Y; Yao B; Yagoda S; Bidollari I; Keane E; Cash E
    J Clin Psychiatry; 2020 May; 81(3):. PubMed ID: 32433835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in length of hospital stay and number of hospitalization before and after the administration of three second-generation antipsychotics long-acting injections in patients with schizophrenia: Mirror-image study.
    Suzuki H; Hibino H; Inoue Y; Takaya A
    Asian J Psychiatr; 2018 Apr; 34():43. PubMed ID: 29635221
    [No Abstract]   [Full Text] [Related]  

  • 16. The possibility of the treatment for long-acting injectable antipsychotics induced severe side effects.
    Omi T; Kanai K; Kiguchi T; Nishida T; Fujimi S; Matsunaga H
    Am J Emerg Med; 2017 Aug; 35(8):1211.e1-1211.e2. PubMed ID: 28460810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical Neuroleptic Malignant Syndrome Associated With Paliperidone Long-Acting Injection: A Case Report.
    Langley-DeGroot M; Joshi Y; Lehman D; Rao S
    J Clin Psychopharmacol; 2016 Jun; 36(3):277-9. PubMed ID: 27043124
    [No Abstract]   [Full Text] [Related]  

  • 18. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.
    Citrome L
    Expert Rev Clin Pharmacol; 2016; 9(2):169-86. PubMed ID: 26573020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophrenia.
    Alphs L; Mao L; Lynn Starr H; Benson C
    Schizophr Res; 2016 Feb; 170(2-3):259-64. PubMed ID: 26742509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia.
    Schreiner A; Aadamsoo K; Altamura AC; Franco M; Gorwood P; Neznanov NG; Schronen J; Ucok A; Zink M; Janik A; Cherubin P; Lahaye M; Hargarter L
    Schizophr Res; 2015 Dec; 169(1-3):393-399. PubMed ID: 26431793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.